| Fractures and survival in multiple myeloma: results from a population-based study S Thorsteinsdottir, G Gislason, T Aspelund, I Sverrisdottir, O Landgren, ... Haematologica 105 (4), 1067, 2020 | 42 | 2020 |
| Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study TE Long, OS Indridason, R Palsson, S Rognvaldsson, TJ Love, ... Blood Cancer Journal 12 (9), 133, 2022 | 38 | 2022 |
| Comorbidities in multiple myeloma and implications on survival: A population‐based study IS Sverrisdóttir, S Rögnvaldsson, S Thorsteinsdottir, GK Gíslason, ... European journal of haematology 106 (6), 774-782, 2021 | 22 | 2021 |
| Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial. First results from the Iceland Screens, Treats, or Prevents … SY Kristinsson, S Rögnvaldsson, S Thorsteinsdottir, ER Reed, ... Blood 138, 156, 2021 | 17 | 2021 |
| Improved survival in myeloma patients–a nationwide registry study of 4,647 patients≥ 75 years treated in Denmark and Sweden KLF Moore, I Turesson, A Genell, TW Klausen, D Knut-Bojanowska, ... Haematologica 108 (6), 1640, 2023 | 9 | 2023 |
| Prevalence of MGUS is high in the istopmm study but the prevalence of IgA MGUS does not increase with age in the way other immunoglobulin subtypes do TJ Love, S Rögnvaldsson, S Thorsteinsdottir, T Aspelund, ER Reed, ... Blood 140 (Supplement 1), 256-258, 2022 | 9 | 2022 |
| Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study AÝ Sigurbergsdóttir, S Rögnvaldsson, S Thorsteinsdóttir, I Sverrisdóttir, ... Haematologica 108 (12), 3392, 2023 | 4 | 2023 |
| Autoimmune diseases are not associated with monoclonal gammopathy of undetermined significance: results of the prospective population-based Istopmm study IS Sverrisdottir, S Thorsteinsdóttir, S Rögnvaldsson, T Aspelund, ... Blood 140 (Supplement 1), 10031-10032, 2022 | 4 | 2022 |
| Defining new reference intervals for serum free light chains in individuals with reduced kidney function: results of the population-based on iceland screens treats or prevents … T Einarsson Long, OS Indridason, R Palsson, S Rögnvaldsson, TJ Love, ... Blood 138 (Supplement 1), 542-542, 2021 | 4 | 2021 |
| Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study TE Long, S Rögnvaldsson, S Thorsteinsdottir, I Sverrisdottir, E Eythorsson, ... Blood 142, 535, 2023 | 3 | 2023 |
| Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma … CH Blimark, K Carlson, C Day, S Einarsdottir, G Juliusson, M Karma, ... Blood 142, 4696, 2023 | 2 | 2023 |
| The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study S Rögnvaldsson, S Thorsteinsdottir, J Oskarsson, E Eythorsson, ... Blood 142, 214, 2023 | 1 | 2023 |
| Long-Term Immunity Against Tetanus and Diphtheria after Vaccination of Allogeneic Stem Cell Transplantation Recipients S Einarsdottir, I Sverrisdottir, K Vaht, T Bergström, M Brune, ... Transplantation and Cellular Therapy 29 (4), 275. e1-275. e5, 2023 | 1 | 2023 |
| Monoclonal gammopathy of undetermined significance and risk of chronic kidney disease: results of the population-based Iceland screens, treats, or prevents multiple myeloma … T Einarsson Long, E Eythorsson, S Rögnvaldsson, O Indridason, ... Blood 140 (Supplement 1), 10108-10109, 2022 | 1 | 2022 |
| Transient M-proteins: epidemiology, causes, and the impact of mass spectrometry: the Istopmm study R Palmason, O Berlanga, JK Sigurdsson, S Rögnvaldsson, ... Blood 140 (Supplement 1), 2338-2340, 2022 | 1 | 2022 |
| Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research-the Importance of Screening: Results from the Population-Based Screening Study … AÝ Sigurbergsdóttir, S Rögnvaldsson, S Thorsteinsdottir, IS Sverrisdottir, ... Blood 138, 1618, 2021 | 1 | 2021 |
| The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study S Thorsteinsdottir, IS Sverrisdottir, G Gislason, O Landgren, I Turesson, ... Blood 132, 4490, 2018 | 1 | 2018 |
| Multiple myeloma and comorbidity: a population-based study IS Sverrisdottir, S Rognvaldsson, SH Lund, I Turesson, M Hultcrantz, ... HAEMATOLOGICA 102, 270-270, 2017 | 1 | 2017 |
| Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland S Rögnvaldsson, A Gasparini, S Thorsteinsdottir, I Sverrisdottir, ... Blood 142 (Supplement 1), 216-216, 2023 | | 2023 |
| Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study S Thorsteinsdottir, I Sverrisdottir, S Rögnvaldsson, S Ekberg, M Hultcrantz, ... Blood 142 (Supplement 1), 3397-3397, 2023 | | 2023 |
